Key Takeaways
- Predictable quarter, AI-led demand building: Revenue grew on a strong order book, with the 12-month backlog up 25% YoY in INR terms, while AI-led opportunities accelerated across all geographies and sectors.
- Middle East headwinds hit EBITDA: Geopolitical instability in West Asia drove bench costs and delayed collections, creating a onetime margin impact that management expects to reverse during the year.
- Healthcare is the swing vertical: A timing gap in the top NHS England account caused a top-5 client decline of 12% YoY, but new data modernization projects are already underway and a ramp back to prior levels is expected from Q2.
- North America approaching an inflection point: Three consecutive quarters of strong order book, headlined by a $25 million, 5-year AI transformation deal, position the region to become a growth engine by H2.
- What to watch next quarter: Whether the U.K. Healthcare ramp materializes as promised, whether Middle East collections reverse, and whether North America sustains its order book momentum for a fourth quarter.
Demand Environment & Order Book
- Broad-based demand holding: The demand environment trended similarly to Q4, with positive traction across sectors; the 12-month order backlog grew 25% YoY in INR and 13% in constant currency, and the company added 13 new customers during the quarter.
- AI-led opportunities accelerating: Over 40 new AI-led opportunities closed in Q1, spanning existing and new customers across all geographies; deal sizes are increasing, and AI deals are emerging from both the installed base and net-new engagements.
- Order book composition: Management does not disclose total contract value but stated that total order book growth is "equally better" directionally; when asked whether excluding the $25 million North America deal the order book appeared flat sequentially, management did not directly address the point, instead highlighting pipeline and funnel improvement.
- U.K. private sector gaining traction: Financial services and banking delivered positive revenue growth from a strong Q4 order book, with AI-led initiatives now shaping private sector demand.
- U.K. public sector stable but under watch: The business grew sequentially on stable existing customers and new local government wins; political leadership changes are being monitored for potential shifts in policy, priorities, or budgets.
Umang Nahata: "As a company, we have a very unique position with our enterprise application transformation business, our strong data practice as well as a phenomenal engineering practice, which makes us uniquely positioned to become a transformation company, starting these transformations from back office and then taking them forward into the entire business."
Vertical & Geographic Performance
| Vertical / Geography | Trend | Commentary |
|---|---|---|
| U.K. Healthcare | ▼ Temporary dip, ▲ expected | NHS England timing gap: old project closed, new data modernization and data platform build starting; ramp back to prior levels expected from Q2 into H2. |
| U.S. Healthcare & Life Sciences | ▬ Turnaround building | A key focus area; turnaround not firm for Q2 but management is "quite sure" for H2. |
| Middle East Healthcare | ▬ Positive order book, uncertain ramp | Healthy order book closure in Q1 including a large deal; ramp-up depends on client readiness for transformation execution amid geopolitical instability. |
| U.K. Financial Services | ▲ Growing | Good wins in Q4 now moving into execution, with net-new opportunities being pursued. |
| North America | ▲ Order book strength | Third consecutive strong quarter; the $25 million AI transformation deal in Salesforce Agentforce is one of the largest in recent quarters; ramp expected by H2FY27. |
| Middle East (overall) | ▼ Severe headwinds | West Asia crisis creating instability and unpredictability; some new order book signed later in the quarter but predictability remains uncertain; bench costs and delayed collections impacted EBITDA. |
- Top 5 clients declined 4% QoQ and 12% YoY, driven entirely by the Healthcare timing gap; management expects a return to usual performance in Q2 and beyond.
- Middle East outlook: The business should at least stay flat; if the geopolitical situation stabilizes, it should move back to growth. Current client signals indicate they want to continue and ramp up.
Umang Nahata: "The Middle East business, on the other hand, continues to face some severe headwinds. As we all know, the West Asia crisis is creating a lot of unstability as well as unpredictability in the market."
Margins & Profitability
- EBITDA impacted by Middle East: Delayed collections, unbilled revenue not invoiced, and a provision for doubtful impact combined with mix changes and U.K. regulatory costs to pressure margins; cost efficiency and a currency tailwind provided a partial offset.
- Middle East margin drag is framed as onetime: Slower-than-anticipated ramp-ups led to bench costs, and the collection slowdown is expected to reverse during the year.
- North America margin path defined: The business is still in investment mode with spending on sales and marketing; management expects it to deliver mid-teens margins once it reaches a quarterly run rate of $28 million to $30 million.
- Q2 margin headwind ahead: Increments are planned and will impact Q2 margins; ESOP grants beginning in Q2 will add an estimated $400,000 to $500,000 per quarter.
- Full-year margin guidance withheld: Management declined to provide steady-state EBITDA or EBIT margin guidance, stating only that it is working on internal cost efficiencies to mitigate a significant portion of the ESOP and increment impact.
- Utilization down 2% sequentially due to order pushouts and the Middle East situation; attrition improved from 17.4% to 16.4%.
Umang Nahata: "As we start reaching close to $28 million to $30 million a quarter run rate is where we believe the North America business will start delivering healthy margins of somewhere around mid-teens."
AI Strategy & Internal Transformation
- Positioning as an AI transformation company: Mastek is steering toward becoming an AI transformation company in its select verticals of healthcare and public sector, leveraging its combination of enterprise application transformation, data practice, and engineering practice.
- Internal AI maturity model: The company has built a proprietary maturity model rating customers from Level 0 to Level 5 based on AI need and maturity; it plans to cover all customers within the next 90 to 180 days.
- Customer Zero initiative underway: Mastek is replacing its own core systems (CRM, recruitment, payables) with an AI-native, internally developed solution described as "Service-as-a-Software."
- Workforce transformation: The company is reshaping its resource skill matrix, transitioning engineers into Forward Deployed Engineers (FDEs) and Forward Deployed Domain Consultants (FDDCs); a large portion of resources will move into these roles going forward.
- Deal sizes increasing: AI deal sizes are growing, with opportunities coming from both existing accounts and net-new engagements across all sectors and geographies.
Umang Nahata: "This journey of transforming Mastek from an engineering powerhouse to a transformation powerhouse is what we are really all in for."
Leadership & Organization
- New COO appointed: Amit Gajwani joined as Chief Operating Officer from LTM, with a mandate focused on delivery transformations, talent pool development, governance, and outcome-focused results.
- Expected impact: Under the new COO, management anticipates "phenomenal change" in the talent pool, stronger governance, and a more outcome-focused organization.
- ESOP grant starting Q2: Estimated impact of $400,000 to $500,000 per quarter; management believes the long-run benefit from leadership and employee stability will outweigh the cost.
Tax Matter
- Income tax assessment received for FY 2022-23: the assessing officer added income of ₹91 crore on account of transfer pricing and ₹32.5 crore on account of domestic tax, with a tax impact of approximately ₹31 crore. An appeal has been filed with the commissioner of income tax appeals on June 26.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| U.K. Healthcare revenue ramp | Return to prior levels and grow from there | Q2 into H2 FY27 |
| Top 5 client performance | Return to usual performance after NHS timing gap | Q2 and beyond |
| North America deal ramp | $25 million, 5-year AI transformation deal begins contributing | H2 FY27 |
| North America margin target | Mid-teens margins at $28M-$30M quarterly run rate | When run rate achieved |
| North America growth inflection | Region turns into a growth engine | H2 FY27 |
| U.S. Healthcare & Life Sciences turnaround | Recovery in the vertical | H2 FY27 |
| Middle East collections reversal | Onetime EBITDA impact reverses | During FY27 |
| ESOP grant impact | $400,000-$500,000 per quarter | Starting Q2 FY27 |
| Increments impact on margin | Wage increases hit Q2 margin | Q2 FY27 |
| AI customer maturity coverage | All customers rated on internal AI maturity model | Next 90-180 days |
| FY27 full-year performance | Better than FY26 | FY27 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | $104.8 million, up 1.2% QoQ |
| Revenue (INR) | ₹985 crore, up 5% QoQ and 7.7% YoY |
| Constant currency revenue growth | 1.8% QoQ |
| Operating EBITDA margin | 15.4% |
| PAT | ₹105.9 crore, 10.6% of total income |
| Basic EPS | ₹34.2, up 14.8% YoY |
| Diluted EPS | ₹33.9, up 15% YoY |
| 12-month order backlog | $310 million, up 3.2% QoQ and 13.3% YoY in USD terms, 25% YoY in INR terms |
| North America total backlog growth | 29.8% QoQ and 23.5% YoY |
| Data, automation and AI business growth | 9.8% QoQ |
| Public sector business growth | 7.9% QoQ |
| U.K. business constant currency growth | 3% QoQ |
| North America business constant currency growth | 2% QoQ, 6% in INR |
| DSO | 75 days, up 2 days QoQ |
| Operating cash flow | ₹27 crore positive |
| Net cash and investment position improvement | ₹200 crore over last 2 quarters |
| Utilization (excluding trainees) | Down 2% QoQ |
| Closing headcount | 4,897, net addition of 167 |
| LTM attrition | 16.4%, down from 17.4% |
| New customers added | 13 |
| Subcontractor cost | 18.5% of revenue, in line with Q4 |
| AI-led opportunities closed | 40-plus |
| North America large deal win | $25 million AI transformation deal, 5-year term |
| U.K. EBIT | ~20% |
| Variable pay paid | ₹107 crore |
| Income tax assessment addition (FY23) | ₹91 crore transfer pricing, ₹32.5 crore domestic tax; tax impact ~₹31 crore |
| ESOP impact estimate | $400,000 to $500,000 per quarter from Q2 |